Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
January 11 2016 - 2:31PM
Business Wire
Scalable, High-Throughput Platform to Offer
Unprecedented Insight into Gene Expression of Individual Cells
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and
Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive
partnership to develop the most comprehensive next-generation
sequencing (NGS) workflow for single-cell analysis. The end-to-end
commercial solution will enable high-throughput sequencing of
thousands of individual cells, traditionally a challenging, costly
and time-consuming process.
Most scientific studies rely on analysis of bulk tissue samples.
These samples are usually composed of multiple cell types with
varying functions. Gene expression data is averaged across cells,
making it difficult to identify differences between cells and to
understand the role of cell variation. Single-cell sequencing
addresses those challenges and provides deeper insight into cell
function, disease progression and therapeutic response. These data
can be important in studies of neurological tissues, for example,
which are known to have hundreds of specialized cell types.
Using Bio-Rad’s best-in-class droplet partitioning technology
and Illumina’s leading NGS technologies, the new solution is
optimized to isolate and barcode single cells for downstream
sequencing. Data analysis is conducted via BaseSpace, Illumina’s
cloud-based genomics computing environment. The solution will be
scalable to isolate significantly larger numbers of single cells
compared to commercially available solutions today, in just a few
minutes at a cost-effective price.
“We welcome the opportunity to collaborate with Illumina, the
global leader in NGS technologies, to develop this long-awaited
platform for single-cell genomics,” said Annette Tumolo, Bio-Rad
Executive Vice President and General Manager, Digital Biology
Center. “Through this partnership, we will deliver a seamless, yet
scalable solution for single-cell gene expression analysis.”
“By collaborating with Bio-Rad, both companies will be able to
serve the significant market for single-cell NGS, enabling
scientists to make groundbreaking advances in gene expression and
beyond,” said Christian Henry, Executive Vice President and Chief
Commercial Officer at Illumina. “Bio-Rad is recognized for
delivering trusted, high-quality products in a market with
increasingly stringent regulations and standards. We look forward
to working with them on such an important endeavor.”
The companies expect to launch the solution in late 2016 or
early 2017.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) develops,
manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic
markets. The company is renowned for its commitment to quality and
customer service among university and research institutions,
hospitals, public health and commercial laboratories, as well as
the biotechnology, pharmaceutical, and food safety industries.
Founded in 1952, Bio-Rad is based in Hercules, California, and
serves more than 100,000 research and healthcare industry customers
through its global network of operations. The company employs more
than 7,600 people worldwide and had revenues exceeding $2.1 billion
in 2014. For more information, please
visit www.bio-rad.com.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties, such as Illumina’s expectations regarding
the launch of any products. Important factors that could cause
actual results to differ materially from those in forward-looking
statements include the application of generally accepted accounting
principles, which are highly complex and involve many subjective
assumptions, estimates, and judgments, and the other factors
detailed in Illumina’s filings with the Securities and Exchange
Commission, including its most recent filings on Forms 10-K and
10-Q, or in information disclosed in public conference calls, the
date and time of which are released beforehand. Illumina assumes no
obligation to update any forward-looking statements after the date
of this release.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our development
and launch of new products. Forward-looking statements generally
can be identified by the use of forward-looking terminology such
as, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,”
“estimate,” “continue,” or similar expressions or the negative of
those terms or expressions, although not all forward-looking
statements contain these words. Such statements involve risks and
uncertainties, which could cause actual results to vary materially
from those expressed in or indicated by the forward-looking
statements. These risks and uncertainties include our ability to
develop and market new or improved products, problems we may
encounter with our supply chain and product quality issues. For
further information regarding our risks and uncertainties, please
refer to the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operation” in
Bio-Rad’s public reports filed with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the fiscal
year ended December 31, 2014 and our Quarterly Report on Form 10-Q
for the fiscal quarter ended September 30, 2015. Bio-Rad cautions
you not to place undue reliance on forward-looking statements,
which reflect an analysis only and speak only as of the date
hereof. We disclaim any obligation to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111006404/en/
Bio-Rad Laboratories, Inc.Tina Cuccia, Corporate
Communications510-724-7000tina_cuccia@bio-rad.comorIllumina,
Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Jennifer
Temple858-882-6822pr@illumina.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Sep 2023 to Sep 2024